Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

NCT07107178 is registered in ClinicalTrials.gov with Biotroy Therapeutics as lead sponsor.

NCT NCT07107178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Safety, Tolerability and Efficacy of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Lead sponsor
Biotroy Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 8, 2025
Completion date
August 31, 2027
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, advanced solid tumor